Venetoclax in 2nd Line after Ibrutinib failure may be more optimal than other treatments

Venetoclax in 2nd Line after Ibrutinib failure may be more optimal than other treatments

User Photo
ASHReport

4 years
689 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Brian Hill, MD, PhD, of Cleveland Clinic discusses updates surrounding CLL, specifically responses to Ibrutinib and Venetoclax as the optimal choice of therapy at the 58th ASH Annual Meeting in San Diego, CA.
Up Next Autoplay
>